Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.

@article{Alderman1997DesipraminePW,
  title={Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.},
  author={Jeffrey Alderman and Sheldon H. Preskorn and David J Greenblatt and Wilma M Harrison and D Penenberg and James H Allison and Menger Chung},
  journal={Journal of clinical psychopharmacology},
  year={1997},
  volume={17 4},
  pages={284-91}
}
In vitro studies have shown that fluoxetine and paroxetine are more potent inhibitors of cytochrome CYP2D6 than sertraline. The pharmacokinetics of desipramine when coadministered with the selective serotonin reuptake inhibitors (SSRIs) paroxetine and sertraline were studied in 24 healthy male volunteers (CYP2D6 extensive metabolizers). Desipramine (50 mg/day) was administered for 23 days in each phase of the crossover study with a 7-day drug-free period between phases. In addition, subjects… CONTINUE READING

From This Paper

Topics from this paper.
31 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Similar Papers

Loading similar papers…